Individual Behavior – Page 2

BIOSECURE Act Clears House Hurdle, Heads to Senate for Vote on Restricting Chinese Biotech Ties

8 months ago talkbio0Tagged BIOSECURE, Biotech Companies, Biotechnology, Chinese Language, Drug Industry, drug supply chain, innovation, National Security, Risk, Senate, United States, US House of Representatives, Voting

BIOSECURE Act, House of Representatives, Senate Vote, Chinese Biotech Companies, National Security Risks, U.S. Pharmaceutical Industry, Biotechnology Innovation, Drug Supply Chain

Lilly’s Tirzepatide Demonstrates Significant Reduction in Diabetes Risk and Sustained Weight Loss in Overweight Adults

8 months ago talkbio0Tagged Adult, Diabetes, Eli, Eli Lilly, Mounjaro, Obesity, Overweight, Prediabetes syndrome, Risk Reduction, Sustained, Weight Loss, Zepbound

tirzepatide, diabetes risk reduction, sustained weight loss, overweight adults, pre-diabetes, obesity, Eli Lilly, Mounjaro, Zepbound

Novo Nordisk’s Wegovy Sales Shortfall: A Rare Setback for the Danish Drugmaker

9 months ago talkbio0Tagged Drug Industry, Nordisk, Performance, Sales - occupational activity, shortfall, Wegovy, Weight-Loss Agents

Novo Nordisk, Wegovy, weight-loss drug, sales shortfall, stock performance, pharmaceutical industry

Nuvation Bio Halts Development of BET Inhibitor NUV-868 Following Interim Phase 1 Data Review

9 months ago talkbio0Tagged BD2-selective BET Inhibitor NUV-868, Bio, Clinical Trials, Effectiveness, Gambling, Inhibitor, Nuvation, oncology drug, Phase 1 (qualifier value), Safety

Nuvation Bio, BET inhibitor, NUV-868, Phase 1 data, oncology drug, safety and efficacy, clinical trials

Senate Fails to Pass Bill Codifying Access to Contraception Amid Republican Opposition

11 months ago talkbio0Tagged Birth, Contraceptive methods, Control Groups, Gegenhalten, Republican, rights, Senate, Voting

Contraception, Senate Vote, Republican Opposition, Reproductive Rights, Birth Control

Legislators Profit from Bill Restricting Chinese Biotech Firms

11 months ago talkbio0Tagged China, Conflict (Psychology), Congress (U.S. Legislature), financial gain, Influence, legislative, trading

Congress, stock trading, China biotech ban, financial gain, legislative influence, conflict of interest.

FDA Greenlights Amgen’s Innovative T Cell Therapy for Aggressive Lung Cancer

11 months ago talkbio0Tagged Aggressive behavior, AMELX gene, amgen, bi-specific, Cancer Therapeutic Procedure, Clinical Trials, Immunotherapy, Malignant neoplasm of lung, Small cell carcinoma of lung, T-Lymphocyte, United States Food and Drug Administration

FDA, Amgen, T cell engager, lung cancer, aggressive, AMG 757, bi-specific T cell engager, small cell lung cancer, immunotherapy, cancer treatment, clinical trials.